Plasma Levels and Diagnostic Utility of Macrophage Colony-Stimulating Factor, Matrix Metalloproteinase-9, and Tissue Inhibitor of Metalloproteinases-1 as New Biomarkers of Breast Cancer.
10.3343/alm.2016.36.3.223
- Author:
Slawomir LAWICKI
1
;
Edyta Katarzyna GLAZEWSKA
;
Monika SOBOLEWSKA
;
Grazyna Ewa BEDKOWSKA
;
Maciej SZMITKOWSKI
Author Information
1. Department of Biochemical Diagnostics, Medical University, Bialystok, Poland. zdb@umb.edu.pl
- Publication Type:Original Article
- Keywords:
Breast cancer;
CA 15-3;
M-CSF;
MMP-9;
TIMP-1
- MeSH:
Adult;
Aged;
Area Under Curve;
Biomarkers, Tumor/*blood;
Breast Neoplasms/*diagnosis/genetics/pathology;
Case-Control Studies;
Female;
Humans;
Macrophage Colony-Stimulating Factor/*blood;
Matrix Metalloproteinase 9/*blood;
Middle Aged;
Mucin-1/blood;
Neoplasm Staging;
Poland;
ROC Curve;
Sensitivity and Specificity;
Tissue Inhibitor of Metalloproteinase-1/*blood
- From:Annals of Laboratory Medicine
2016;36(3):223-229
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Macrophage colony-stimulating factor (M-CSF), matrix metalloproteinase-9 (MMP-9), and its specific tissue inhibitor - tissue inhibitor of metalloproteinases-1 (TIMP-1) may play an important role in the pathogenesis and spread of cancer. We investigated the plasma levels of M-CSF, MMP-9, and TIMP-1 in comparison with a commonly accepted tumor marker CA 15-3 in breast cancer patients and in control groups. METHODS: The cohort included 110 breast cancer patients in groups at stages I-IV. The control group consisted of 50 healthy volunteers and 50 benign tumor patients. Plasma levels of M-CSF, MMP-9, and TIMP-1 were determined by using ELISA, while CA 15-3 concentrations were determined by using chemiluminescent microparticle immunoassay (CMIA). RESULTS: The results showed significant differences in concentrations of the analyzed parameters and in levels of CA 15-3 between the groups of breast cancer patients and the two control groups. Diagnosis using these markers was equal to that using CA 15-3 in terms of sensitivity, predictive values of positive and negativetest results (PPV, NPV) and area under the ROC curve (AUC) in the studied groups. The diagnostic specificities of MMP-9, TIMP-1, M-CSF, and CA 15-3 showed equally high values (95%). The combined use of all tested parameters with CA 15-3 resulted in increased sensitivity, NPV, and AUC, especially in the combination of M-CSF with tumor markers (76%, 64%, and 0.8653). CONCLUSIONS: These findings suggest the tested parameters are useful in the diagnosis of breast cancer patients (except stage I), when combined with CA 15-3.
